In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


BD hospital infection settlement

This article was originally published in The Gray Sheet

Executive Summary

Becton Dickinson and French diagnostics firm BioMérieux settle an arbitration dispute initiated by BioMérieux in April to terminate an agreement granting detection method rights for methicillin resistant Staphylococcus aureus, a common hospital-acquired infection, to BD subsidiary GeneOhm Sciences, BD notes in an Aug. 8 Securities and Exchange Commission filing. BD/GeneOhm retains access to use the technology under the settlement (1"The Gray Sheet" April 30, 2007, p. 9)...

You may also be interested in...

Dispute Arises Over Hospital-Acquired Infection Tests

French diagnostic firm BioMérieux is attempting to renege on a licensing agreement with Becton Dickinson relating to methods for detecting one of the most common infections picked up in hospitals, according to BD

Pandemic Response In US Consumer Health Market: OTC Pain Relief And Cough/Cold Purchases

Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.

venBio Raises $394m To Fund Biopharmas Through Human Proof-Of-Concept

Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts